WINTON GROUP Ltd Invests $3.23 Million in Edwards Lifesciences Co. (NYSE:EW)

WINTON GROUP Ltd bought a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 43,627 shares of the medical research company’s stock, valued at approximately $3,230,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC increased its holdings in shares of Edwards Lifesciences by 199.1% in the third quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 2,923 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $825,000. Private Trust Co. NA raised its holdings in Edwards Lifesciences by 8.6% in the 3rd quarter. Private Trust Co. NA now owns 2,931 shares of the medical research company’s stock valued at $193,000 after acquiring an additional 233 shares during the period. Townsquare Capital LLC lifted its position in Edwards Lifesciences by 20.5% during the third quarter. Townsquare Capital LLC now owns 5,208 shares of the medical research company’s stock worth $344,000 after acquiring an additional 886 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Edwards Lifesciences by 6.0% during the third quarter. Glenmede Trust Co. NA now owns 381,168 shares of the medical research company’s stock worth $25,153,000 after acquiring an additional 21,505 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on EW shares. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Truist Financial reissued a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group increased their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $71.17 on Friday. The firm has a 50 day simple moving average of $71.47 and a 200 day simple moving average of $70.46. The company has a market cap of $41.84 billion, a price-to-earnings ratio of 10.21, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.